meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - all population
mGC or mGEJC - L1 - HER2 neg/PDL1 positive
2
mGC or mGEJC - L1 - HER2 negative
1
mGC or mGEJC - L1 - HER2 positive
mGC or mGEJC - L1 - PDL1 positive
4
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population
4
mGC or mGEJC - L2 - PDL1 positive
1
mGC or mGEJC - maintenance (M)
mGC or mGEJC - M - HER2 negative
1
mGC or mGEJC - M - HER2 neg/PDL1 positive
1
gene alteration defined cancer
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
All patients
Age < 65y (younger)
Age > 65y
Asian type
cancer location (esophagus)
cancer location (gastric)
cancer location (gastro-esophageal)
ECOG 0
ECOG 1
Gender, female
Gender, male
metastasis (liver )
PD-L1 < 1%
PD-L1 > 1%
previous gastrectomy
previous gastrectomy NO
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
STRAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Blood creatinine increased TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dizziness TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Dysgeusia TRAE (grade 3-4)
Endocrine disorders TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Gastrointestinal disorders TRAE (grade 3-4)
Hepatobiliary disorders TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Mucosal inflammation TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Peripheral sensory neuropathy TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Renal and urinary disorders TRAE (grade 3-4)
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4)
Skin and subcutaneous tissue disorders TRAE (grade 3-4)
Stomatitis TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Weight decreased TRAE (grade 3-4)
deaths (OS)
mGC or mGEJC - L1 - HER2 neg/PDL1 positive
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - HER2 neg/PDL1 positive
versus Standard of Care (SoC)
nivolumab plus SoC vs. Standard of Care (SoC)
2
0.71
[0.59; 0.86], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
mGC or mGEJC - L1 - HER2 negative
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - HER2 negative
versus Standard of Care (SoC)
nivolumab plus SoC vs. Standard of Care (SoC)
1
0.80
[0.68; 0.94], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
mGC or mGEJC - L1 - PDL1 positive
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - PDL1 positive
versus placebo plus SoC
pembrolizumab alone vs. placebo plus SoC
1
0.69
[0.49; 0.97], 1 RCT, I2=0%
unassessable degree of certainty
pembrolizumab plus SoC vs. placebo plus SoC
2
0.85
[0.70; 1.03], 1 RCT, I2=0%
inconclusive result
versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC)
1
0.91
[0.75; 1.11], 1 RCT, I2=0%
inconclusive result
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open